print logo

Saladax Biomedical, Inc. Expands Distribution of My5-FU in Egypt and MENA

Eilaf Pharma will serve as theexclusive distributor of Saladax's My5-FU(TM) diagnostic test, which measures levels of a widely-used anti-cancer drug.
Eilaf Pharma | 24.04.2012
Saladax Biomedical, Inc., a privately held company developing and commercializing novel diagnostic assays to achieve the promise of personalized medicine for new and existing therapeutics, announced today that Eilaf Pharma S.A.E. will serve as exclusive distributor of Saladax's My5-FU(TM) diagnostic test, which measures levels of a widely-used anti-cancer drug, 5-fluorouracil (5-FU), in the blood of cancer patients, in Egypt and throughout the Middle East North African (MENA) region.

"Over the past year, we've been able to successfully expand our distribution of My5-FU in multiple markets worldwide creating new sales channels in more than a dozen countries," said Adrienne Choma, Esq., Sr. VP and chief marketing officer of Saladax. "We're happy to be working with Eilaf to provide patients with colorectal cancer in the region a new option to help maximize the therapeutic effect of their chemotherapy."

My5-FU enables oncologists to determine the optimal dose of 5-FU for each individual patient, thereby increasing the effectiveness of the drug and lessening the risk of severe toxicity and side effects. My5-FU is the first of Saladax's innovative dose management tests commercially available.

Haytham Abuelfadl, M.D., MIBA, Eilaf's Managing Director, said, "We're delighted to be offering Saladax's unique diagnostic test in Egypt and the other markets in our region. We hope that with this tool, our oncologists will be able to provide their patients with the most appropriate course of chemotherapy possible." Eilaf is a new joint stock health care company that promotes products to market- leading positions in Egypt and the MENA region.

About My5-FU

Saladax's first commercially available test for innovative dose management; My5-FU measures levels of 5-fluorouracil (5-FU), a widely used chemotherapy drug used in conjunction with other drugs in first-line therapy for colorectal cancer and other solid tumors. The assay technology enables oncologists to determine the optimal dose of 5-FU for each individual patient, thereby increasing the effectiveness of the drug and lessening the risk of severe toxicity and side effects.